Abstract Malignant pleural mesothelioma (MPM) is an aggressive, primary pleural malignancy with poor prognosis, hypothesized to originate from a chronic inflammatory state within the pleura. Similar to what has been observed in other solid tumors (melanoma, ovarian and colorectal cancer), clinical and pre-clinical MPM investigations have correlated anti-tumor immune responses with improved survival. As such, a better understanding of the complex MPM tumor microenvironment is imperative in strategizing successful immunotherapies. Herein, we review the immune responses vital to the development and progression of MPM, as well as assess the role of immunomodulatory therapies, highlighting recent pre-clinical and clinical immunotherapy investigations.
Introduction
Malignant pleural mesothelioma (MPM) is an aggressive primary pleural malignancy with median survival of 9-12 months, hypothesized to originate from a chronic inflammatory process within the pleura. Currently, even with trimodality therapy (chemotherapy, surgical resection, and thoracic radiation), median survival is only 17 months [1, 2] . Despite poor prognosis even after aggressive therapies, MPM patients with anti-tumor immune responses survive longer, with improved survival associated with increased CD8
? tumor-infiltrating lymphocytes [3, 4] . Immunosuppressive cytokines and regulatory T cells (T regs ) are also hypothesized to infiltrate the tumor microenvironment, dampening anti-tumor immune function and promoting MPM tumor growth [5] . Understanding the interplay between pro-and anti-tumorigenic immune cells in the MPM microenvironment is vital in developing novel therapies in MPM. Our review highlights the immune responses that are vital to the development and progression of MPM, as well as assesses the complex interplay between immune cells and immunomodulatory therapies, in an attempt to provide investigators with key information in the quest to develop novel immunotherapies for MPM.
Frustrated phagocytosis and the development of MPM
The association between asbestos exposure and subsequent development of mesothelioma has been documented in multiple animal species via inhalation of, or subcutaneous, intrapleural, and intraperitoneal inoculation with, asbestos fibers [6] [7] [8] [9] . Inhaled asbestos fibers present within the lung cause infiltration of circulating macrophages into the pleural space, which try to phagocytose the inhaled foreign bodies [10] . In the effort to clear asbestos fibers, reactive oxygen species are generated, with subsequent production of inflammatory cytokines and increased recruitment of immune cells to sites of inflammation within the pleura [11] [12] [13] [14] . Macrophages' repeated phagocytotic efforts fail to clear the asbestos fibers, resulting in continued generation of reactive oxygen species and secretion of pro-inflammatory cytokines [14] . This process, often referred to as ''frustrated phagocytosis,'' represents a chronic inflammatory state that has been shown to generate malignant transformation of mesothelial cells in vitro ( Fig. 1) [10, 15] . Similar ''frustrated phagocytosis'' was observed following the introduction of carbon nanotubules into the peritoneal cavity of mice, subsequently inducing inflammation and fibrosis to an equal or greater extent than long asbestos fibers [16] [17] [18] . As single and multiwalled carbon nanotubules are increasingly being used in electronic and other consumer products, these studies raised concerns, although the inhalational threshold for the observed changes is not yet known.
Tumor-infiltrating immune cells in human MPM
Immune responses within the tumor microenvironment are increasingly implicated as a determining factor in tumor progression and aggressiveness. Higher degrees of tumorinfiltrating CD3
? in ovarian cancers and intratumoral CD45RO
? cells in colorectal cancer were associated with prolonged survival [19, 20] . In a recent investigation from our laboratory, the role of the inflammatory response in both tumor and stroma was assessed in 175 epithelioid MPM patient specimens [21] . Routine hematoxylin-and eosin-stained slides were evaluated for both acute and chronic inflammation within MPM tumor and stromal components. Patients with high stromal, chronic inflammatory responses were observed to have improved median overall survival, as compared to patients with low chronic inflammatory responses (19.4 vs. 15 .0 months, respectively). Importantly, on multivariate analysis, chronic stromal inflammation remained an independent predictor of survival within our study cohort (P = 0.02, HR = 0.659, 95% CI 0.464-0.937). For the first time, this investigation evaluated the inflammatory response within both the tumor and stroma, providing insight into the prognostic value of inflammatory responses in epithelioid MPM. The analysis of tumor specimens from MPM patients has revealed associations between the presence of immune cell infiltrates and patient outcome, allowing pro-and anti-tumorigenic activity to be attributed to specific immune cell types (Table 1) . In this section, we highlight the roles of various immune cells as determined in patient specimens.
Cytotoxic CD8
? T-cell infiltration
The correlation of the presence of tumor-infiltrating CD8
? cells with MPM patient survival was demonstrated by immunohistochemistry in extrapleural pneumonectomy specimens. Yamada et al. [4] , in a multivariate analysis examining 27 patients undergoing extrapleural pneumonectomy as initial treatment, demonstrated CD8 ? lymphocyte infiltration as an independent prognostic factor. In addition, Yamada et al. observed positive MHC I expression in all MPM specimens, possibly accounting for the effective anti-tumor activity of CD8
? cells. The protective association of tumor-infiltrating CD8
? T cells has also been demonstrated in patients who have received induction chemotherapy. In an immunohistochemical evaluation of 32 patients who underwent induction chemotherapy followed by extrapleural pneumonectomy, a high density of tumor-infiltrating CD8
? cells was found to be an independent predictor of prolonged survival (3-year overall survival: 83% vs. 28% for high vs. low infiltration, respectively) [3] . Furthermore, this study observed that high levels of tumor-infiltrating CD8
? T cells were correlated with reduced frequency of mediastinal lymph node metastasis. Interestingly, the authors observed higher CD8
? lymphocyte infiltration in patients receiving cisplatin/pemetrexed (currently the most efficacious MPM chemotherapy regimen) versus cisplatin/vinorelbine. These results suggest that strategies that promote tumor-infiltrating CD8
? T cells may be beneficial to MPM patients. and their prognostic significance are quite scarce [5] . Hegmans et al. confirmed the presence of significant numbers of T regs on immunohistochemistry; however, no correlation with survival was possible due to the small number of tumor samples examined. Additionally, the dual and seemingly contradictory role of tumor-associated mast cells has been detailed in breast, lung, and ovarian cancer [22] [23] [24] [25] [26] , but a paucity of data exist on mast cell function in MPM and their role is unknown. Studies elucidating the natural history of T reg and mast cell infiltration upon MPM progression are required.
Regulatory T cells (T regs ) and mast cells
Peripheral immune cell relative ratio as a predictive biomarker in MPM Peripheral blood neutrophil-to-lymphocyte ratio (NLR), a marker of systemic inflammation shown to be prognostic in solid malignancies [27, 28] , was also found to be an independent predictor of survival on multivariate analysis in the recent study examining 173 MPM patients undergoing systemic therapy [29] . One-year survival rate for NLR \ 5 and C5 was 60% versus 26%, with median overall survivals of 16.7 versus 6.6 months, respectively. Furthermore, subgroup analysis revealed a 3-month survival advantage in patients whose NLR normalized posttreatment. The clinical utility of NLR in mesothelioma, however, remains to be seen, as the promise of this simple, low-cost, peripheral blood test needs to be reproduced by other investigators. Although MPM was initially thought to be a poorly immunogenic tumor due to a paucity of reported cases of spontaneous remissions [30] , clinical investigation into MPM patient samples demonstrates that increased intratumoral CD8
? lymphocyte infiltration is beneficial in MPM patients' prognosis.
Murine immunotherapeutic interventions
As analysis of the correlation between immune cell infiltration in the tumor microenvironment and patient outcome is complex and difficult to interrogate due to the rarity of MPM, murine models have been used to evaluate disease characteristics and novel treatments. Investigators have attempted immunotherapy and immunomodulation as a rational means not only to promote the infiltration of tumors with cytotoxic immune cells but also to reduce the effects of immunosuppressive cells within the MPM tumor microenvironment.
Immune cell-modulating therapies (Table 2 ; Fig. 2) T regs depletion CD25, a marker of activation on T lymphocytes, is constitutively expressed by T regs [31] ; the presence of CD4
? CD25 ? T regs has been implied in the inhibition of anti-tumor immunity and has also been associated with worse prognosis in several cancers [32] [33] [34] [35] . Depletion of T regs using intratumoral or intraperitoneally injected anti-CD25 antibody in mice prior to intraperitoneal inoculation with mesothelioma tumor resulted in the restriction of tumor growth and significantly increased median survival from 19 to 33 days [5, 36, 37] . Flow cytometric analysis of tumor cell suspensions showed that T reg depletion resulted in a large accumulation of intratumoral interferon-c (IFNc)-producing CD4
? and CD8 ? cytotoxic T cells, which the investigators proposed to be responsible for the observed anti-tumor response [36] . CD4
? cells appeared to be important mediators that lure CD8
? cells into the tumor microenvironment, as depletion of CD4
? cells significantly reduced intratumoral CD8
? cell infiltration by approximately 2.5-fold [36] .
Beneficial observations of T reg depletion prior to tumor implantation were reproduced by Anraku et al. [38] .
Enhanced survival was dependent on tumor infiltration by CD8
? cells, as CD8-depleted mice were ineffective at mounting a robust anti-tumor response despite T reg blockade. T reg depletion by anti-CD25 antibody did not improve survival, however, if administered as a monotherapy in established MPM tumors. Following the observation of increased T reg percentage in response to pemetrexed therapy, Anraku et al. hypothesized that T reg blockade in concert with pemetrexed may prove effective. In fact, combination of pemetrexed chemotherapy and anti-CD25 antibody administration-given intraperitoneally 4 days after tumor injection-functioned synergistically, improving survival in mice with established MPM tumors. In addition to pemetrexed, gemcitabine also eliminated established MPM tumors with the addition of T reg depletion via cyclophosphamide or anti-CD25 antibody [39] . Again, anti-tumor response was demonstrated to be reliant upon CD8
? T cells, with nearly unaffected tumor growth occurring in CD8
? depleted mice. Cyclophosphamide, a chemotherapeutic with established immunostimulatory properties including the ability to selectively deplete T regs , was found to sensitize MPM tumor cells to TRAIL-mediated apoptosis, suggesting that anti-tumor immune responses provoked by cyclophosphamide depend on increased tumor cell susceptibility, rather than effector cell proliferation [40] . A more recent investigation observed retarded MPM tumor growth when either anti-CD25 antibody or cyclophosphamide was given following cisplatin cycles [41] . These data implied that T reg depletion between cisplatin cycles may hinder MPM tumor cell repopulation, potentially improving outcomes. Although T reg depletion combined with chemotherapeutic agents was beneficial in MPM, T reg depletion by anti-CD25 did not improve the efficacy of intratumoral IL-2 immunotherapy in an investigation by Jackaman et al. [42] .
Although human studies are scarce, the aforementioned investigations imply that the balance between cytotoxic T cells and T regs within the MPM tumor microenvironment contributes to whether a tumor will be subject to (a) an immunosuppressive environment in which unrestrained tumor growth can occur or (b) an anti-tumor setting in which cytotoxic T cells can elicit an effective cytotoxic immune response.
Tumor-associated macrophage depletion
In various solid tumors, in the presence of appropriate cytokines or ligands, macrophages can polarize into two types: M1 and M2 tumor-associated macrophages (TAMs) [43] . M1 TAMs demonstrate immunostimulatory properties and confer enhanced tumor resistance and cytotoxicity, while M2 TAMs secrete immunosuppressive cytokines, promote angiogenesis, and support tumor progression [43] , invasion, and metastasis and overall have been associated with poorer prognosis in lung, breast, prostate, and cervical cancer [44] [45] [46] [47] [48] [49] [50] . The role of TAMs in MPM is still largely unknown, however. Interaction with MPM cells appears to shift mature macrophages toward a M2 phenotype, characterized by poor antigen presentation and increased immunosuppressive activity [51] . Upon cocultivation with MPM cells, macrophages released a significant amount of prostaglandin E 2 , an arachidonic acid metabolite with considerable anti-inflammatory properties. The presence and production of prostaglandin E 2 contribute to T reg development, promoting an immunosuppressive tumor microenvironment [52, 53] . With this background, the depletion of pro-tumorigenic M2-TAMs by liposomeencapsulated clodronate (CLIP) in a peritoneal mesothelioma model was performed [54] . Mice with established tumors demonstrated a 50% reduction in both the number of tumors and tumor burden when treated with CLIP compared to control treatments, although CLIP treatment of mice bearing established tumors did not prolong survival. The results of this study imply that TAMs contribute to the development and progression of mesothelioma; however, additional investigations are needed to clarify the role of TAMs in MPM.
Dendritic cell vaccination
Dendritic cell (DC) vaccination exploits the ability of DC to present antigens and initiate a cascade of immunologic events leading to the destruction of cells expressing these specific tumor antigens [55, 56] . Hegmans et al. [57] showed that tumor lysate-pulsed DCs can prevent engraftment and halt mesothelioma progression by stimulating tumor-directed CD8 ? cytotoxicity. The protective effect of DC immunotherapy appeared to be long-lived as tumor rechallenge after 3 months in this cohort did not result in subsequent mesothelioma outgrowth. Given therapeutically, in mice with established peritoneal mesothelioma, CAR chimeric antigen receptor, CCL2R CCL2 receptor, CLIP liposome-encapsulated clodronate, CPA cyclophosphamide, DC dendritic cell, IFN interferon, TAM tumor-associated macrophage, TLR Toll-like receptor, T reg regulatory T cells DC treatment was associated with decreased velocity of mesothelioma outgrowth and prolonged survival. Furthermore, adoptively transferred CD8 ? T cells from mice treated with tumor lysate-pulsed DCs retained tumor-specific cytotoxicity when injected into mesothelioma-bearing mice, prolonging survival in mice when given either 1 week before or 2 days after tumor inoculation. Veltman et al. [58] demonstrated that combination treatment with DC immunotherapy and cyclophosphamide potentiated therapy, significantly improving mice survival compared with cyclophosphamide or DC immunotherapy monotherapy. Timing and dose of cyclophosphamide administration have previously been demonstrated to be vital to whether the drug displays immunosuppressive or immunostimulatory effects [59] .
Tumor antigen-targeted immunotherapy
Although tumor lysates contain a repertoire of MPMassociated antigens, it is possible that critical MPM antigens are neither shed nor highly expressed. Therefore, studies have sought to identify MPM antigens as specific targets for immunotherapies. Two such candidate cancer antigens are mesothelin and Wilms' tumor-1 (WT-1) protein. These proteins demonstrate tumor-specific overexpression and the ability to elicit both active and humoral immune responses [60] [61] [62] [63] [64] . Mesothelin, a cell-surface cancer-associated antigen with uncertain function, is overexpressed in the vast majority of epithelioid MPM [65] . While it is highly expressed in MPM, normal mesothelin expression is restricted to the mesothelial lining of the peritoneum, pleura, and pericardium. In addition, soluble mesothelinrelated protein (SMRP) may be detected in the serum of patients with MPM and may prove a useful biomarker to follow treatment response [66, 67] . Studies in a murine model of mesothelin-expressing epidermoid carcinoma suggest that targeting mesothelin-expressing cells using SS1P, a recombinant immunotoxin consisting of the variable fragment (Fv) of an anti-mesothelin antibody fused to a Pseudomonas exotoxin, can cause tumor regression with enhanced anti-tumor efficacy observed when combined with chemo-or radiotherapy [68, 69] . Similarly, MORAb-009, a chimeric mouse-human monoclonal IgG 1j antibody with high affinity for human mesothelin, was found to prevent the adhesion of mesothelin-expressing MPM cells, conferring antibody-dependent cellular cytotoxicity upon cells exhibiting mesothelin positivity [70] .
Another approach targeting tumor-associated antigens is the chimeric antigen receptor (CAR). CARs are comprised of a tumor antigen-binding domain linked to an intracellular signaling domain able to activate T cells [71] . CARs unite high-affinity antigen recognition with T-cell signal transduction, two functions that fundamentally arise from separate complexes, the TCR ab-heterodimer and the CD3 complex. The extracellular, antigen-binding domain is usually derived from a murine or human monoclonal antibody, but other receptors have also been utilized. It follows that antigen recognition by CARs is not MHC-restricted, as is the case for TCR-mediated antigen recognition. Antigen binding by CARs activates the signaling cascade that induces antigen-specific cytolysis, effector cytokine secretion, and T-cell proliferation. A recent investigation utilizing mesothelin-targeted CARs to target mesothelinexpressing MPM (derived from the malignant pleural effusion of a mesothelioma patient) showed that these genetically engineered T cells were able to proliferate, express effector cytokines, and eliminate tumor cells both in vitro and in vivo in a flank MPM model [72] . Engineered T lymphocytes demonstrated anti-tumor efficacy at effectorto-target ratios of approximately 1:10 and 1:40 in vitro and in vivo, respectively. In vivo, both intratumoral administration and intravenous administration were found to be efficacious, with intravenous administration being associated with delayed treatment response, however. In an attempt to improve T-cell trafficking into MPM tumors, T cells bearing mesothelin-targeted CARs were transduced to express the CCL2 chemokine receptor, as CCL2 was found to be highly expressed by MPM tumors [73] . In mice with established flank MPM tumors, mesothelin CAR-transduced T cells bearing CCL2 receptors infiltrated tumors significantly greater than T cells transduced with mesothelin CARs only, improving anti-tumor efficacy.
No pre-clinical investigations are available regarding the targeting of WT-1 in MPM.
Cytokine therapy

Interferon-b
Type I interferons (interferon-a/b) possess direct and indirect anti-viral, anti-proliferative, and immunomodulatory properties and in particular have been implied in the regulation of both CD4
? and CD8 ? T cells during the initial phases of antigen recognition [74] . The direct antiproliferative effects of interferon-b gene transfer upon MPM cells were demonstrated by Odaka et al. [75] . Recombinant interferon-b administration led to statistically significant improved survival; however, no survival advantage was observed for low-versus high-dose treatment. Single-dose adenovirally encoded interferon-b gene transfer was also shown to prolong survival in a peritoneal MPM model. Mice treated with interferon-b gene transfer retained long-term immunity and anti-tumor response, as tumor re-challenge approximately 2 months afterward did not cause MPM tumor growth upon flank injection with MPM cells. Tumor killing appeared to be dependent on CD8
? T cells as CD8 ? -depleted mice demonstrated tumor growth and survival nearly equivalent to untreated controls. Furthermore, the therapeutic efficacy of interferon-b gene transfer was nearly obviated in SCID mice (which lack B and T cells). Neo-adjuvant adenovirus encoding interferon-b significantly reduced tumor recurrence and resulted in improved 25-day, tumor-free survival in mice [76] .
Interleukin-2
The pro-inflammatory cytokine interleukin-2 (IL-2) is produced by activated T cells, resulting in increased proliferation, survival, and development of cytotoxic T lymphocytes [77, 78] . IL-2 administration increased survival in treated mice bearing small (*10 mm 3 ) flank tumors at treatment initiation, while mice bearing large (*30 mm 3 ), established MPM tumors failed to demonstrate improved survival [79] . Importantly, IL-2-responsive mice remained tumor free for greater than 2 months afterward, in addition to resisting subsequent tumor re-challenge 2-6 months following initial tumor inoculation. IL-2-treated small tumors were associated with increased number and cytotoxicity of tumor-infiltrating CD8
? T lymphocytes, as well as decreased tumor-associated vasculature; however, treatment failed to increase antigen presentation within tumor-draining lymph nodes when compared with untreated control mice. Histopathologic examination of tumor specimens from mice subjected to CD8
? T-cell depletion did not demonstrate a reduction in tumor-associated vasculature, implying a key role of CD8
? T cells in IL-2-mediated anti-tumor mechanisms.
Combination of intratumoral IL-2 and anti-CD40 antibody immunotherapy was attempted by Jackaman et al. [79] [80] [81] to overcome the limitations of monotherapy and apply treatment to larger tumors. In this study, over 80% of mice exhibited complete tumor regression without subsequent progression. The anti-CD40 treatment primarily recruited B cells, whereas IL-2 treatment increased CD4 ? and CD8
? T-cell infiltration into the MPM tumor microenvironment, as determined by flow cytometry. In addition to CD8
? T cells, mice treated with combination therapy were observed to have significantly increased infiltration neutrophils as well. In mice bearing small MPM flank tumors, depletion of both CD4
? and CD8 ? cells did not prevent the efficacy of combination IL-2 and anti-CD40 treatment, implying other effector mechanisms may be important in early tumor eradication. Combination treatment was also effective against large ([25 mm 3 ) tumors that were resistant to IL-2 or anti-CD40 monotherapy. Furthermore, mice treated with combination therapy resisted tumor re-challenge at multiple subsequent time points thereafter. CD4
? and CD8 ? cell depletion in mice bearing large tumors treated with combination therapy nearly obviated the anti-tumor efficacy of the regimen, while CD4
? -depleted mice retained the efficacy of treatment, again supporting the vital role which CD8
? cells play in the elimination of large tumors treated with IL-2 and anti-CD40 treatment. Neutrophil infiltration of large tumors was also shown to be required in order to eradicate tumors, as depletion of neutrophils also prevented tumor regression, implying that both CD8
? and neutrophils, together, are required for an effective anti-tumor response.
Interleukin-12
Interleukin-12 (IL-12) is a multifunctional cytokine vital to cell-mediated immunity, playing a key role in driving T H 1 differentiation while promoting T-cell cytotoxicity, proliferation, and interferon-c production [82] . IL-12 has been shown to produce significant anti-tumor immune responses in pre-clinical studies and is an attractive cytokine for use in MPM immunotherapy [83, 84] . Caminschi et al. [85] investigated the anti-tumor effects of systemic IL-12 administration in a flank MPM model. Synchronous systemic administration of IL-12 during tumor inoculation prevented tumor growth in approximately 70% of treated mice. Furthermore, half of IL-12-treated mice resisted tumors re-challenge, implying that long-term anti-tumor effects had occurred. Intratumoral IL-12 injections into established tumors also resulted in the reduction in tumor volume and reduced growth; however, this effect was temporary. The IL-12-mediated anti-tumor effects relied on the presence of both CD4
? and CD8 ? T cells as depletion of either resulted in increased tumor growth. A subsequent study by Caminschi et al. [86] assessed the anti-tumor efficacy of IL-12 by transfecting a murine MPM cell line with IL-12 genes, inducing local IL-12 production within the tumor microenvironment. Local production of IL-12 appeared to prevent tumor formation, as IL-12-transfected tumor cells were unable to form tumors in BALB/c mice. IL-12-transfected MPM cells were able to form tumors, however, in athymic nude mice, providing further evidence to the key role which T lymphocytes play in the anti-tumor response.
Cytokine therapy has demonstrated efficacy in improving median survival in murine models. Depletion studies have documented the importance of both CD4
? and CD8
? lymphocytes in mediating the anti-tumor effects of cytokine therapy. Furthermore, investigations have revealed evidence of cytokine therapy conferring long-term immunity as demonstrated by resistance to tumor re-challenge.
Cytokine/chemokine blockades A dual strategy aimed at bolstering the anti-tumor immune response while dampening the immunosuppressive forces within the tumor environment may be an effective way to permit unabated anti-tumor immunity. Studies by Fridlender et al. [87] suggest that blocking CCL2 and CCL12-chemoattractants that attract T regs and dampen CD8 ? T-cell effector functions-augments anti-tumor immune responses by inhibiting T regs trafficking and immunosuppression within the tumor microenvironment. Blocking CCL2/12 alone with intraperitoneally administered monoclonal antibodies had limited efficacy, leading to significantly slowed tumor growth, but not regression. When combined with mesothelin-vaccine immunotherapy, however, CCL2/ 12 blockade resulted in a significant decrease in both tumor burden (*50% cure rate) and intratumoral T regs , as well as an increase in the number and activity of intratumoral CD8
? T cells. Importantly, blockade of CCL2/12, in concert with vaccine immunotherapy, induced *twofold higher expression of the pro-inflammatory molecules CXCL10, ICAM, IL-10, IL-12, IFN-c, and TNF-a.
A similar approach has used TGF-b blockade to potentiate immunotherapy [88] . TGF-b is produced by MPM at high levels and is believed to play a pivotal role in generating an immunosuppressive tumor microenvironment via promoting T reg-mediated immunosuppression, impeding tumor infiltration by T cells, and inhibiting anti-tumor T-cell functions [89] [90] [91] . ? T-cell infiltration and activation and increased expression of pro-inflammatory cytokines, chemokines, and cell adhesion molecules.
TGF-b has also been shown to polarize macrophages toward a pro-tumorigenic M2 phenotype [92] and theorized to polarize neutrophils toward a pro-tumorigenic state N2 phenotype (as opposed to the anti-tumor, pro-inflammatory N1 phenotype); as such, TGF-b blockade's effect on tumor-associated neutrophil (TAN) phenotype was examined in a recent study [93] . TANs derived from flank MPM tumors in mice treated with TGF-b blockade demonstrated an elevated mRNA expression of pro-inflammatory molecules (TNF-a, CCL3, and ICAM-1), as compared to untreated control MPM tumors. Interestingly, arginase levels were decreased 2-to 5-fold in TANs isolated from mice treated with TGF-b blockade, compared to untreated controls; the immunosuppressive functions of arginase have been shown previously [94] . The aforementioned data led the authors to hypothesize that TGF-b blockade resulted in the polarization of TANs toward the anti-tumor, N1 phenotype. Depletion of TANs in untreated mice (that is, removal of the immunosuppressive, N2 TANs) led to *twofold increase in CD8
? T-cell activation as shown by flow cytometry, as well as a small reduction in tumor growth. Conversely, depletion of pro-inflammatory, N1 TANs in mice treated with TGF-b blockade significantly blunted T-cell activation, allowing for increased tumor growth. The results of this study imply that following TGFb blockade, TANs that exhibit an anti-tumor phenotype (N1 TANs) are recruited into the MPM tumor microenvironment, leading to elaboration of pro-inflammatory cytokines with subsequent activation of intratumoral CD8
? T cells. Although the MPM tumor-neutrophil relationship has not been extensively studied, it warrants further investigation as the pro-inflammatory environment setup by N1 TANs may be an important mechanism for tumor regression.
Immuno-adjuvant therapies
An alternative approach to immunotherapy aims to enhance the intrinsic activity of immune system. In a flank model of MPM, Currie et al. [95] intratumorally injected Toll-like receptor (TLR) ligands to activate DCs and induce T-cell-dependent cytotoxicity in a type I interferon (IFN)-dependent manner. Intratumorally administered TLR7 agonist induced systemic, CD8
? T-cell and type-I IFN anti-tumor responses that prevented primary MPM tumor growth but not the growth of distant, untreated tumor foci [96] . The anti-tumor effects were obviated following CD8
? cell depletion as well as in nude mice. The relative paucity of intratumoral CD4
? T cells, along with the lack of observed systemic CD4
? T-cell activation in mice with response, implied that CD4 ? T-cell assistance may be required for a robust systemic anti-tumor response. Indeed, distant untreated tumor foci were targeted when an agonistic anti-CD40 antibody (mimicking CD4
? T-cell assistance) was administered systemically in combination with local TLR7 agonist. The authors hypothesized that systemic anti-CD40 antibody administration, a surrogate for CD4
? T helper cells, increased tumor cell sensitivity to cytotoxic T cells or increased the quality of the CD8 ? T-cell response.
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is an inhibitory molecule found on T cells, hypothesized to regulate T-cell activation [97] . Anti-CTLA-4 antibodies (ipilimumab and tremelimumab) that block interaction between CTLA-4 and its associated ligands (B7.1 and B7.2) have been observed to promote anti-tumor immune responses in pre-clinical investigations of various solid tumors [98] [99] [100] . Recent clinical successes in treating melanoma with ipilimumab (Yervoy) have led to its FDA approval [101, 102] . While the use of CTLA-4 has been investigated in other non-melanoma solid tumors, there have yet to be any notable pre-clinical investigations of its use in MPM models. Interestingly, however, a phase II clinical trial utilizing tremelimumab as second-line therapy for unresectable MPM is in progress in a single Italian
Although the vast majority of these studies were performed in either flank or peritoneal MPM models, orthotopic MPM models have been previously well described [103] [104] [105] and should be utilized in future studies to more accurately mimic the pleural tumor microenvironment.
Human immunotherapy trials
In this section, we discuss the use of cytokine-and cellularbased immunotherapies and analyze their utility in mesothelioma treatment as determined by recent clinical trials (Table 3) .
Cytokine-based therapy
As a result of the aforementioned promising pre-clinical results, a recent phase I clinical trial assessing intrapleural interferon-b gene transfer in patients with MPM and malignant pleural effusions was performed [106] . Successful interferon-b gene transfer was detected in seven of ten patients. Variable anti-tumor immune responses were observed in seven out of ten MPM patients, as demonstrated by the activation of natural killer cells and cytotoxic T cells, as well as the generation of antibodies to MPMassociated antigens. An update of this cohort, following repeated intrapleural administration of adenoviral encoded Goey [109] interferon-b, published more recently observed that nine out of ten MPM patients had demonstrated humoral immune responses to MPM-associated antigens following treatment [107] . While the majority succumb to progressive disease, three out of ten MPM patients were alive at 18, 39, and 42 months following treatment, demonstrating either mixed response or stable disease on follow-up PET imaging. Another study by Boutin et al. [108] suggested that intrapleural administration of recombinant interferon-c may be beneficial to MPM patients with early (stage I) disease; eight patients demonstrated significant histologic response and nine patients yielded partial responses for an overall response rate of 20%. A phase I-II clinical trial utilizing intrapleural administration of IL-2 in 23 stage I-IIA patients detailed some anti-tumor efficacy and an acceptable side-effect profile, with high intrapleural IL-2 levels observed with low corresponding serum levels [109] . Pleural effusion-derived mononuclear cells displayed significantly higher lymphokine-activated killer (LAK) activity than peripherally obtained mononuclear cells. No correlation between IL-2 dose and LAK activity or clinical response was observed. Additional phase II clinical trials assessing intrapleural administration of IL-2 in MPM have been carried out reporting marginal histopathologic responses and modest improvements in median survival [110] [111] [112] [113] . Unfortunately, immunologic parameters following treatment were not detailed in these investigations. The results from clinical trials assessing intrapleural IL-2 efficacy in MPM are conflicting and, although some increase in overall survival appears to be achieved in these studies, the potential of IL-2 to significantly impede disease progression has not been convincingly demonstrated. While phase II intrapleural IL-2 has demonstrated some effectiveness in treating MPM, other routes of administration (intravenous and/or subcutaneous) as first-line treatment have failed to do so [114, 115] . In a group of 60 MPM patients who received preoperative intrapleural IL-2 treatment, a significantly higher number of T regs was observed in surgical specimens, as compared to 33 patients who did not receive IL-2 [116] . Within the IL-2-treated group, high T regs , defined as greater than the median on immunohistochemical assessment, was correlated with both decreased patient survival and increased tumor recurrence on subgroup analysis. Furthermore, pre-operative, intrapleural IL-2 therapy in MPM was associated with a high level of tryptase-positive mast cell infiltration, which correlated with both increased overall survival and time to progression [117] . When taken together, the density of tryptase-positive mast cell and T reg infiltration was able to more accurately predict prognosis than either parameter alone; a high tryptase-positive mast cell and low T reg tumor infiltrate were found to possess the best overall patient survival. The results from these studies must be interpreted with caution however, since IL-2 is known to induce a wide range of immunomodulatory effects, several of which may contribute to the aforementioned survival benefit.
Active immunization
Based on pre-clinical studies demonstrating the efficacy of DC-based immunotherapy [57] , Hegmans et al. [118] conducted a small, phase I clinical trial where DCs were pulsed with autologous tumor lysate, matured ex vivo, and then administered intradermally and intravenously to MPM patients following cytoreductive surgery and cisplatinbased chemotherapy. Although DCs immunotherapy was well tolerated and appeared to elicit an immunologic response, no survival benefit was noted. Interpreting this data is challenging, however, due to small sample size (n = 10) and inclusion of a highly selected patient population; only patients with the epithelioid subtype of MPM and who had either a partial response or stable disease following multimodality therapy were included. To specifically target MPM tumors, cancer antigens, such as mesothelin and WT-1, that are highly expressed and thought to be physiologically relevant for the tumor may be targeted. Recently, the NCI cancer panel identified WT-1 as the leading tumor-associated antigen to be targeted [119] . Studies assessing WT-1 as a target for immunotherapy have been carried out in leukemias and have shown clinical efficacy [62, 63, 120] and are the basis for expanding these therapies to MPM. Since MPM expresses WT-1 at high levels [121, 122] and provokes an immune response [63] , it is an attractive target for MPM immunomodulatory therapy. A phase I peptide vaccination clinical trial from Memorial Sloan-Kettering Cancer Center for unresectable or relapsed MPM patients is ongoing. In these patients, inoculation with WT-1 peptide elicited WT-1-specific CD4 and CD8 T-cell responses, with minimal toxicity [123] .
Immunotoxin therapy
Based on promising pre-clinical results targeting mesothelin with the immunotoxins SS1P and MORAb-009, clinical trials were initiated [65, [124] [125] [126] . Phase I clinical trials in patients with advanced MPM, pancreatic, and ovarian cancers, utilizing both bolus and continuous intravenous administration of SS1P while well tolerated, have shown only modest clinical responses [124, 125] . Similarly, a phase I MORAb-009 dose-escalation trial in MPM, pancreatic, and ovarian cancer patients failed to demonstrate any complete or partial responses [126] . Preclinical studies, however, have demonstrated significant anti-tumor efficacy using combination of MORAb-009 and chemotherapy treatment [70] ; as such, a multicenter phase II clinical trial utilizing cisplatin/pemetrexed with MORAb-009 in MPM patients is currently ongoing [Clinicaltrials.gov Identifier-NCT00738582].
Despite early pre-clinical results utilizing genetically engineered T cells to target MPM-associated tumor antigens, the efficacy of adoptive T-cell therapy has yet to be evaluated in MPM patients.
Conclusion
Lymphocytic infiltration has been demonstrated in multiple solid tumors (melanoma, ovarian and colorectal cancers), with type and density of the immune cell infiltrate correlated with clinical outcomes [19, 20, [127] [128] [129] [130] . These investigations lend support and provide rationale for developing immunotherapies that will increase immune cell infiltration within solid tumors. Human clinicopathologic and preclinical studies have provided evidence that lymphocytic invasion influences prognosis in MPM as well. In comparison with other solid malignancies, there continues to be mounting evidence that the MPM tumor microenvironment is highly immunosuppressive, with the presence of immunosuppressive cytokines (in particular, TGF-b) and immune cells (T regs , M2 TAMs, and N2 TANs) playing key roles. These observations imply that a better understanding of the immunostimulatory and immunoinhibitory components of the MPM tumor microenvironment will be helpful in strategizing a successful immunotherapy.
In MPM, studies have implied that the beneficial antitumor effects are CD8
? lymphocyte-mediated and optimal CD8
? lymphocyte efficacy is likely dependent upon CD4
? lymphocyte assistance. T regs also play an active role in MPM pathogenesis and blockade may prove to be an effective therapy in the future. However, the role of TAMs, TANs, and the human MPM tumor microenvironment is relatively unexplored and should be the focus of future investigations. Pre-clinical studies utilizing immunotoxins and immunotherapy have shown promising results in murine MPM models, with evidence amassing that adjuvant immunomodulation may be needed for success within the clinical realm. Success with tumor-associated antigentargeted therapy has been limited to the pre-clinical stage, however. Clinical studies have demonstrated intrapleural cytokine therapies to be safe and well tolerated, but their efficacy is unproven. While different approaches are available, this review suggests that an efficacious immunotherapy may result from a treatment that will both enhance the anti-tumor activity and dampen the pro-tumor effects of the immune system. Immunotherapy offers a promising therapeutic approach, either alone or in concert with current standardof-care treatments for MPM. Perhaps more importantly, as pleural MPM is a regionally aggressive malignancy, investigating the utility of regionally administered therapies may prove effective in delivering high potency treatment while minimizing systemic toxicities.
